![]()
|
|
||||||||
J. Biol. Chem., Vol. 262, Issue 10, 4683-4688, Apr, 1987
U Galili, CB Basbaum, SB Shohet, J Buehler and BA Macher
The Gal alpha 1-3Gal structural determinant has been found to have a unique
distribution in mammals. Although this determinant is abundantly expressed
by erythrocytes and nucleated cells of many mammals, it has not been
detected in human cells. However, our previous studies (Galili, U.,
Rachmilewitz, E. A., Peleg, A., and Flechner, I. (1984) J. Exp. Med. 160,
1519-1531; Galili, U., Clark, M. R., and Shohet, S. B. (1986) J. Clin.
Invest. 77, 27-33) have suggested that this epitope is present in small
amounts and may be involved in immune-mediated destruction of senescent
human erythrocytes. To have a means for exploring this possibility and for
studying the species and tissue distribution of this epitope we have raised
a monoclonal antibody (Gal- 13) which specifically binds to glycoconjugates
with a nonreducing terminal Gal alpha 1-3Gal disaccharide. Mice were
immunized with rabbit erythrocytes, which express an abundance of
glycoconjugates with Gal alpha 1-3Gal epitopes. Clones were screened with a
solid-phase binding assay (enzyme-linked immunosorbent assay) for
antibodies which bound to ceramide pentahexoside (Gal alpha 1-3Gal beta
1-4GlcNAc beta 1-3-Gal beta Gal beta 1-4Glc1-1Cer) but not to ceramide
trihexoside (Gal alpha 1-4Gal beta 1-4Glc1-1Cer). Gal-13 bound to a number
of neutral glycosphingolipids from rabbit and bovine erythrocytes. These
glycosphingolipids have previously been shown to be a family of linear and
branched polylactosamine structures, which have non-reducing terminal Gal
alpha 1-3Gal epitopes. The antibody did not bind to the human blood group B
glycolipid, Gal alpha 1-3(Fuc alpha 1-2)Gal beta 1- 4GlcNAc beta 1-3Gal
beta 1-4Glc1-1Cer, and, therefore, branching at the penultimate galactose
blocks Gal-13 binding. However, after removal of the fucose from the B
antigen Gal-13 recognized the resulting derivative. Other Gal alpha 1-3Gal
glycosphingolipids with an isogloboside or globoside core structure were
not recognized by Gal-13 suggesting that the antibody binds to Gal alpha
1-3Gal carried by a lactosamine core structure. Gal-13 has been used to
demonstrate that the Gal alpha 1-3Gal ceramide pentahexoside has been
evolutionarily conserved in red cells of animals up to the stage of New
World monkeys but is not found in Old World monkey red cells.(ABSTRACT
TRUNCATED AT 400 WORDS)
Identification of erythrocyte Gal alpha 1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. O. Speak, M. Salio, D. C. A. Neville, J. Fontaine, D. A. Priestman, N. Platt, T. Heare, T. D. Butters, R. A. Dwek, F. Trottein, et al. From the Cover: Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals PNAS, April 3, 2007; 104(14): 5971 - 5976. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Galili, K. Wigglesworth, and U. M. Abdel-Motal Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines J. Immunol., April 1, 2007; 178(7): 4676 - 4687. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. W. Cooling, K. E. Walker, T. Gille, and T. A. W. Koerner Shiga Toxin Binds Human Platelets via Globotriaosylceramide (Pk Antigen) and a Novel Platelet Glycosphingolipid Infect. Immun., September 1, 1998; 66(9): 4355 - 4366. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Duk, B. B. Reinhold, V. N. Reinhold, G. Kusnierz-Alejska, and E. Lisowska Structure of a Neutral Glycosphingolipid Recognized by Human Antibodies in Polyagglutinable Erythrocytes from the Rare NOR Phenotype J. Biol. Chem., October 26, 2001; 276(44): 40574 - 40582. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |